NOV 18, 2017 02:29 PM PST

Targeting Prostate Specific Membrane Antigens in Renal Cell Carcinoma

Prostate Specific Membrane antigens (PSMA) encoded by the gene FOLH1, and also known as glutamate carboxypeptidase 2, are transmembrane proteins that have had great utility in the molecular imaging of prostate cancer using positron emission tomography (PET) and detecting its presence, as well as being targeted by small molecules with radionuclides, and exploited therapeutically.  PSMA is expressed normally in non-malignant prostate epithelial cells, but is well known to be upregulated in prostate tumors.  Aside from being expressed in cells of the prostate, PSMA is expressed by endothelial cells including those of the vasculature networks of other solid tumors such as renal cell carcinoma (RCC).

RCC is the most common type of kidney cancer occurring in adults, accounting for nearly 95% of all cases.  Patients presenting with localized RCC typically undergo partial or in some cases complete removal of the effected kidney, and have a survival rate of 65-90%.  This number decreases dramatically if the disease has advanced and metastasized to other organs.  As with many cancers, typically by the time a RCC patient presents in the clinic they have advanced disease.  This is largely because RCC tends to be asymptomatic until later stages of progression, so determining markers for early detection would be valuable and potentially life-saving.  Two scientists at the James Buchanan Brady Urological Institute and Department of Urology at Johns Hopkins University in Baltimore, Maryland have utilized the fact that PSMA is expressed in the neovasculature of RCC, and used PSMA-targeted PET radio labels to successfully image RCC in their patients, and with greater sensitivity than traditional imaging modalities allowing them to detect metastatic disease in clear cell RCC (ccRCC).  Further, Sophia Spatz, a researcher at the Clinic of Urology, University Hospital Bonn in Bonn, Germany, and her colleagues published findings that PSMA was not only expressed in a cohort of 257 RCC patient tumors by histological staining, but the levels of expression correlated with disease stage and grade, as well as overall survival.  These findings were further confirmed by RNA expression data from The Cancer Genome Atlas.

These reports lend evidence that PSMA may also have utility in diagnostic imaging and therapeutic targeting in RCC in addition to its more traditional use in prostate cancer.  If it could be effectively targeted in RCC, this holds potential to offer a therapeutic intervention even for advanced disease for which there are currently no good treatment options, and to date remains incurable.    

Sources: Nature Reviews Urology, Wikipedia, Journal of Urology, Pixabay, Youtube/Health Tips

 

 

 

 

About the Author
You May Also Like
NOV 22, 2018
Drug Discovery
NOV 22, 2018
Breast Cancer Drug 'Tamoxifen' Brings Hope To Muscle Disease
Tamoxifen is currently a drug used in the treatment of breast cancer, and has been used in patients for many years. Now, latest research has indicated that...
DEC 16, 2018
Health & Medicine
DEC 16, 2018
Important Biomedical Research At Risk Of Being Defunded
In September the Department of Health and Human Services (D.H.H.S.) released a statement citing “serious regulatory, moral and ethical considerations...
DEC 17, 2018
Health & Medicine
DEC 17, 2018
Microglial Priming And Pain
Microglia are in primed states when injury happens and acute exposure to opioids activates them further creating pain sensitivity....
FEB 08, 2019
Drug Discovery
FEB 08, 2019
Apsirin Use Prevents Colorectal Cancer
In a study published in the American Journal of Medicine, the U.S. Preventive Services Task Force (USPSTF) concluded that aspirin use decreases the risk of...
FEB 17, 2019
Drug Discovery
FEB 17, 2019
Drug Improves Muscle Properties
Currently, adults over 65 are an increasingly growing segment in many countries. In the United States, the elderly population will increase by 40 percent w...
FEB 20, 2019
Drug Discovery
FEB 20, 2019
Cocktail of Common Antibiotics Fights E. coli Infections
Researchers at the Technical University of Denmark are working towards finding new methods for battling antibiotic resistant bacteria. Currently, many dise...
Loading Comments...